Quantum BioPharma’s Lucid-MS Candidate Highlighted for Potential to Address Unmet Need in Multiple Sclerosis Treatment

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a BioMedWire editorial examining emerging approaches to treating multiple sclerosis (MS), a disease affecting more than 2.9 million people globally. The article highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath targeted by MS. The program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in the treatment of the disease.

The editorial, available at https://ibn.fm/KdvrI, underscores the potential of Lucid-MS, which is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Multiple sclerosis is a chronic autoimmune disorder where the immune system attacks the protective covering of nerves, leading to communication problems between the brain and the rest of the body. Current treatments focus on managing symptoms and slowing progression, but there is no cure. Lucid-MS represents a potential breakthrough by targeting the underlying mechanism of the disease.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The company also invented UNBUZZD(TM), an over-the-counter product aimed at alcohol misuse, and retains a 19.84% ownership stake in Unbuzzd Wellness Inc., along with royalty payments from sales of unbuzzd(TM).

The inclusion in the BioMedWire editorial highlights the growing interest in Quantum’s approach to MS treatment. With Phase 2 trials on the horizon, the company is poised to advance a therapy that could potentially change the landscape for millions of patients. The editorial notes that Lucid-MS is a first-in-class therapy, meaning it operates through a mechanism distinct from existing treatments, which could offer new hope for those who do not respond well to current options.

For investors and stakeholders, the latest news and updates relating to Quantum BioPharma are available at the company’s newsroom at https://ibn.fm/QNTM. As the company moves forward with its clinical development program, the potential implications for the MS community are significant, offering a possible new avenue for treatment that addresses the root cause of the disease rather than just its symptoms.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Quantum BioPharma’s Lucid-MS Candidate Highlighted for Potential to Address Unmet Need in Multiple Sclerosis Treatment.

The post Quantum BioPharma’s Lucid-MS Candidate Highlighted for Potential to Address Unmet Need in Multiple Sclerosis Treatment appeared first on citybuzz.